Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6020524 | Journal of Neuroimmunology | 2014 | 8 Pages |
Abstract
Laquinimod is an immunomodulatory drug with neuroprotective potential. We used the animal model of experimental autoimmune neuritis (EAN) in the Lewis rat to study the effects of laquinimod treatment. After immunization with the neuritogenic peptide aa 53-78 of P2 myelin protein, preventive therapy with 12.5Â mg/kg laquinimod once daily inhibited neuritis in clinical and electrophysiological terms. Histology corroborated a lower degree of inflammatory lesions and demyelination in the sciatic nerve. The proportion of FoxP3-positive regulatory T cells in the peripheral lymph nodes of treated rats remained unchanged. We conclude that laquinimod may represent a therapeutic option in human autoimmune neuropathies.
Keywords
MMPMNCVVLA-4VCAM-1BNBLFA-1MNCCIDPCMAPEANi.pAIDPEAEGBSAPCCFANF-kBICAM-1PDCexperimental autoimmune neuritisacute inflammatory demyelinating polyneuropathyAntigen presenting cellsexperimental autoimmune encephalomyelitisinflammationimmunotherapyautoimmunityvery late antigen-4IntraperitoneallyCNSmotor nerve conduction velocityDendritic cellsMononuclear cellsGuillain–Barré syndromecentral nervous systemperipheral nervous systemnuclear factor kappa-light-chain-enhancer of activated B cellsLaquinimodMatrix metalloproteinasesChronic inflammatory demyelinating polyneuropathyintercellular adhesion molecule-1vascular cell adhesion molecule-1compound muscle action potentialPNScomplete Freud's adjuvant
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kalliopi Pitarokoili, Björn Ambrosius, Lisa Schrewe, Liat Hayardeny, Michael Hayden, Ralf Gold,